T1	Value 33 44	30-80 years
T3	Condition 72 87	Type 2 diabetes
T4	Condition 131 151	diabetic nephropathy
T7	Value 196 209	≤ 2000 mg/day
T2	Person 45 51	of age
R1	Has_value Arg1:T2 Arg2:T1	
T5	Value 179 191	≥ 100 mg/day
T6	Measurement 153 178	urinary albumin excretion
R2	Has_value Arg1:T6 Arg2:T5	
T8	Scope 153 209	urinary albumin excretion ≥ 100 mg/day but ≤ 2000 mg/day
R4	Subsumes Arg1:T4 Arg2:T8	
T9	Measurement 213 245	Glomerular filtration rate (GFR)
T10	Value 246 257	≥ 40 ml/min
R5	Has_value Arg1:T9 Arg2:T10	
T11	Qualifier 275 327	Modification of Diet in Renal Disease (MDRD) formula
R6	Has_qualifier Arg1:T9 Arg2:T11	
T12	Temporal 329 349	in the last 4 months
R7	Has_temporal Arg1:T9 Arg2:T12	
T13	Person 352 358	Female
A1	Optional T13
T14	Condition 376 390	postmenopausal
T15	Procedure 410 432	bilateral oophorectomy
T16	Procedure 451 472	surgically sterilized
T17	Procedure 476 491	hysterectomized
R9	OR Arg1:T16 Arg2:T17	
T18	Temporal 492 528	at least 6 months prior to screening
T19	Scope 451 491	surgically sterilized or hysterectomized
R10	Has_temporal Arg1:T19 Arg2:T18	
R11	OR Arg1:T15 Arg2:T19	
R8	OR Arg1:T14 Arg2:T15	
T20	Scope 376 528	postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening
R12	Has_scope Arg1:T13 Arg2:T20	
T21	Procedure 612 632	hypertensive therapy
A2	Optional T21
T22	Measurement 645 659	blood pressure
T23	Value 660 674	≥ 135/85 mm Hg
T24	Value 679 703	lower than 170/105 mm Hg
T25	Scope 660 703	≥ 135/85 mm Hg but lower than 170/105 mm Hg
R14	AND Arg1:T21 Arg2:T22	
R15	Has_scope Arg1:T22 Arg2:T25	
T26	Drug 756 784	antihypertensive medications
T27	Qualifier 749 755	stable
R16	Has_qualifier Arg1:T26 Arg2:T27	
T28	Temporal 789 823	at least 8 weeks prior to baseline
R17	Has_temporal Arg1:T26 Arg2:T28	
T29	Qualifier 835 850	Newly diagnosed
T30	Condition 851 872	hypertensive patients
T31	Measurement 885 899	blood pressure
T32	Value 900 914	≥ 135/85 mm Hg
T33	Value 919 943	lower than 170/105 mm Hg
T34	Scope 900 943	≥ 135/85 mm Hg but lower than 170/105 mm Hg
R19	Has_scope Arg1:T31 Arg2:T34	
R20	Has_qualifier Arg1:T30 Arg2:T29	
A3	Optional T29
A4	Optional T30
T35	Drug 994 1018	hypoglycemic medications
T36	Temporal 1023 1056	at least 8 weeks prior to Visit 2
R21	Has_temporal Arg1:T35 Arg2:T36	
T37	Qualifier 987 993	stable
R22	Has_qualifier Arg1:T35 Arg2:T37	
T38	Non-query-able 1069 1321	Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.
T39	Measurement 1323 1344	Oral body temperature
T40	Value 1362 1374	35.0-37.5 °C
R23	Has_value Arg1:T39 Arg2:T40	
R3	Has_value Arg1:T6 Arg2:T7	
T43	Scope 835 872	Newly diagnosed hypertensive patients
R13	AND Arg1:T43 Arg2:T31	
T44	Temporal 944 964	at baseline (Day -1)
T45	Reference_point 947 964	baseline (Day -1)
R18	Has_index Arg1:T44 Arg2:T45	
R24	Has_temporal Arg1:T31 Arg2:T44	
T46	Reference_point 815 823	baseline
R25	Has_index Arg1:T28 Arg2:T46	
T47	Reference_point 1049 1056	Visit 2
R26	Has_index Arg1:T36 Arg2:T47	
T41	Observation 1392 1416	written informed consent
T48	Temporal 1417 1445	prior to study participation
T49	Reference_point 1426 1445	study participation
R27	Has_index Arg1:T48 Arg2:T49	
R28	Has_temporal Arg1:T41 Arg2:T48	
T42	Observation 1450 1474	Able to communicate well
T50	Observation 1501 1542	comply with the requirements of the study
